On the protease gene, no major mutation was detected. However, many minor mutations, feature of the...
-
Upload
buck-grant -
Category
Documents
-
view
216 -
download
3
Transcript of On the protease gene, no major mutation was detected. However, many minor mutations, feature of the...
On the protease gene, no major mutation was
detected. However, many minor mutations, feature
of the non B strains, were present and the most
important are: M36I, K20I/R/T, H69K, I13V,
L63P/T/H/S/G, I93L, L10I/V, G16E and V77I.
HIV-1 drug resistance among naives patients in Senegal
BackgroundHAART has dramatically improved survival and quality of life among people living with HIV and AIDS globally. However, drug resistant mutations of HIV are a great challenge to the benefits of HAARTIn Senegal, HAART is available in the capital city since 1998 and gradually in the decentralized settings since 2001. Secondary resistance can be compared with the rich countries. But, circulating of primary resistance is no studies.
ConclusionARV reduces morbidity and mortality of HIV infected patients but resistance can occur Risk of transmission of resistants virus
This study showed an emergence of drug resistance strains in HIV naïve patients (2%). Resistance surveillance and genetic diversity study are necessary and strategies to preserve the first line drugs are needed. .
ResultsCharacteristic of population and strains
87 (83, 65%) of 104 patients, were women and 17 were men. Age is only known for 97 patients with an average of 32 years. The median of LTCD4 was of 562 cellules/mm3.
Phylogenetic analysis showed a predominance of the recombinant CRF02_AG with 64 strains (61,5%) but also the presence of other strains : A(n=1), A3, (n=2), B (n=4), C (n=8), D’ (n=1), CRF06 (n=2), CRF11_cpx (n=2), of the recombinants unique CFR02/A3 (n=5), F/U (n=1), G/U/G (n=1) CRF36_cpx /CRF02_AG (n=2), U/ CRF02_AG (n=4), U/ CRF37_cpx (n=1),
Methodology104 naive HIV-1 patients were recruited in 2 mainclinical care center in 2003, 2005 and 2007In 2003-2005, they were chosen on the basis of a rateof LTCD4/mm3 superior or equal to 350.In 2007, criteria are TCD4 superior or equal to 500and/or age under 25 years.2003- 2005 : a 1850 pb fragment including PR gene et
420 first AA of RT gene was amplified by a nested RT-PCR
2007-2008 : nested RT-PCR was done separatly for PR and RT gene
RéférencesDerache A, Maiga A., et coll. Evolution of genetic diversity and drug resistance mutation HIV-1 among untreated patients from Mali Between 2005-2006. PMID: 18556706
Laurent C, Ngom Gueye NF, Ndour CT et coll. Long-term benefits of highly active antiretroviral therapy in Senegalese HIV-1-infected adults. J Acquir Immune Defic Syndr. 2005 Jan 1;38(1):14-7
Nicaise Ndembi, Awet Abraha, et coll. Molecular Characterization of Human Immunodeficiency Virus Type 1(HIV-1) and HIV-2 in Yaounde´, Cameroon: Evidence of Major Drug Resistance Mutations in Newly Diagnosed Patients Infected with Subtypes Other than Subtype B. CLINICAL MICROBIOLOGY, Jan. 2008, p. 177–184
Toni T, Masquelier B et coll. HIV-1 ANTIRETROVIRAL drug resistance in recently infected patients in Abidjan, Cote Ivoire: A 4-years survey 2002-2006. PMID: 1799113
Objectives- To analyze the presence of mutations associated to ARV among newly diagnosed immunocompetent HIV positive patients.- To study strains polymorphism in both Protease (PR) and RT gene
Detection of drug resistance mutations
On RT gene, 1 sample presents major mutation
(G190E) conferred a high level resistance to EFV
and NVP.
Ten samples present minor resistance mutations of
which 4 associated to the NRTIs, 2 (E44D, V108I,
K238KN and T215ST) and 6 to the non nucleoside
(V179E, T69PT, K103EK, E138A A62V and
V118I).
According to the Stanford the K238N and the
K103EK conferred an intermediate resistance to the
DLV and the NVP. The T215ST conferred an
intermediate resistance to the ZDV and the D4T.
.
Figure 2: Phylogenetic tree of 2005
Table 2: Drug resistance mutations on RT gene 2005
AcknowledgmentsANRS 1257 financial projectANRS 12134 financial projectContact : [email protected], [email protected]
Figure 3: Phylogénétic tree
Figure 1: Characterization of strains
A: 2005 B: 2007-2008
Table 3: Drug resistance mutations on RT gene of 2007-2008
Figure 4 : Drug resistance mutations on PR gene 2008
Leye N.1, Diop-Ndiaye H.1, Kebe K.1, Guindo P.M.1, Watara B.3, Ngom Guèye N.F.2, Diouf E B2.., Diallo S.1, Diop-Diongue O.1, Diaw-Diouf N.A.1, Gaye-Diallo A.1,
Sembène M.3, Touré-Kane C1. and Mboup S.1
1Laboratory Bactériology-Virology, University of Dakar N.3, - 2CTA OPALS, CHU de Fann, Sénégal- 3 Center of halth of Roi Baudouin
Phylogenetic analysis were done by neighbour-joining method and sequences were submitted on Stanford HIVdb and were compared with the ANRS v2006.7 and Rega v6.4.1algorithms and the IAS Resistance Testing-USA panel (09/2007)
ERxample of set of primers used for the long fragment and the DNA analyzer : Applied Biosystems 3100 Avent
Viral Check Workshop 21th-27th June Dakar Senegal